Immunotherapy for Malignant Gliomas

Cellular immunotherapy for malignant gliomas.

INTRODUCTION Cancer immunotherapy has made much progress in recent years. Clinical trials evaluating a variety of immunotherapeutic approaches are underway in patients with malignant gliomas. Thanks to recent advancements in cell engineering technologies, infusion of ex vivo prepared immune cells have emerged as promising strategies of cancer immunotherapy. AREAS COVERED Herein, the authors r...

Biologic principles of immunotherapy for malignant gliomas.

The most common primary brain neoplasm is glioblastoma multiforme, which is associated with a dismal prognosis. Despite the recommended treatment regimen of aggressive surgical resection, radiation, and chemotherapy, the median survival remains approximately only 14 months. Due to these minimal improvements in survival of patients despite recent advances in conventional treatments, new modaliti...

Immunotherapy for Malignant Gliomas: A Roadmap for the Future

Since many decades, medical doctors and researchers have been intrigued by the possible beneficial contribution of the immune system in the long-lasting combat against cancer. Both in the cellular and humoral immunity arms, powerful tools are available to target the cancer cell. Moreover, the gradual shift of a focus on aspecific reinforcement of the innate immune system towards a specifically ...

Adoptive cellular immunotherapy for the treatment of malignant gliomas.

UNLABELLED The median survival for adults with recurrent primary malignant gliomas is 56 weeks following surgery, radiation, and chemotherapy. Generally, reoperation can extend the median survival an additional 26-32 weeks. We have developed an aggressive treatment program that utilizes low doses of interleukin-2 (IL-2) combined with ex vivo activated killer cells (LAK) infused via an indwellin...

Anti-Angiogenesis, Gene Therapy, and Immunotherapy in Malignant Gliomas